Lipid-based antifungal agents: current status
- PMID: 11254895
- DOI: 10.2174/1381612013398031
Lipid-based antifungal agents: current status
Abstract
Immunocompromised patients are well known to be predisposed to developing invasive fungal infections. These infections are usually difficult to diagnose and more importantly, the resulting mortality rate is high. The limited number of antifungal agents available and their high rate of toxicity are the major factors complicating the issue. However, the development of lipid-based formulations of existing antifungal agents has opened a new era in antifungal therapy. The best examples are the lipid-based amphotericin B preparations, amphotericin B lipid complex (ABLC; Abelcet), amphotericin B colloidal dispersion (ABCD; Amphotec or Amphocil), and liposomal amphotericin B (AmBisome). These formulations have shown that antifungal activity is maintained while toxicity is reduced. This progress is followed by the incorporation of nystatin into liposomes. Liposomal nystatin formulation is under development and studies of it have provided encouraging data. Finally, lipid-based formulations of hamycin, miconazole, and ketoconazole have been developed but remain experimental. Advances in technology of liposomes and other lipid formulations have provided promising new tools for management of fungal infections.
Similar articles
-
The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.Oncol Nurs Forum. 1998 Jan-Feb;25(1):35-48. Oncol Nurs Forum. 1998. PMID: 9460772 Review.
-
Liposomal and lipid-based formulations of amphotericin B.Leukemia. 1996 Jun;10 Suppl 2:s93-6. Leukemia. 1996. PMID: 8649062 Review.
-
The use of lipid formulations of amphotericin B for systemic fungal infections.Leukemia. 1996 Oct;10(10):1570-5. Leukemia. 1996. PMID: 8847891 Review.
-
Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations.Antimicrob Agents Chemother. 1998 Jun;42(6):1412-6. doi: 10.1128/AAC.42.6.1412. Antimicrob Agents Chemother. 1998. PMID: 9624486 Free PMC article.
-
In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.J Antimicrob Chemother. 1999 Sep;44(3):397-401. doi: 10.1093/jac/44.3.397. J Antimicrob Chemother. 1999. PMID: 10511410
Cited by
-
OMICS and Other Advanced Technologies in Mycological Applications.J Fungi (Basel). 2023 Jun 19;9(6):688. doi: 10.3390/jof9060688. J Fungi (Basel). 2023. PMID: 37367624 Free PMC article. Review.
-
Drug Delivery (Nano)Platforms for Oral and Dental Applications: Tissue Regeneration, Infection Control, and Cancer Management.Adv Sci (Weinh). 2021 Feb 5;8(8):2004014. doi: 10.1002/advs.202004014. eCollection 2021 Apr. Adv Sci (Weinh). 2021. PMID: 33898183 Free PMC article. Review.
-
Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone.Pharm Res. 2009 Jun;26(6):1324-31. doi: 10.1007/s11095-009-9841-2. Epub 2009 Feb 13. Pharm Res. 2009. PMID: 19214716
-
Optimizing efficacy of amphotericin B through nanomodification.Int J Nanomedicine. 2006;1(4):417-32. doi: 10.2147/nano.2006.1.4.417. Int J Nanomedicine. 2006. PMID: 17722276 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources